Abstract
Rationale: There are few treatment options for severe COVID-19 pneumonia. Opaganib is an oral treatment under investigation. Objective: Evaluate opaganib treatment in hospitalized patients with severe COVID-19 pneumonia. Methods: A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted in 60 sites worldwide from August 2020 to July 2021. Patients received either opaganib (n=230; 500mg twice daily) or matching placebo (n=233) for 14 days. Main Outcome Measurements: Primary outcome was the proportion of patients no longer requiring supplemental oxygen by day 14. Secondary outcomes included changes in the World Health Organization Ordinal Scale for Clinical Improvement, viral clearance, intubation, and mortality at 28- and 42-days. Main Results: Pre-specified primary and secondary outcome analyses did not demonstrate statistically significant benefit (except for time to viral clearance). Post-hoc analysis revealed the fraction of inspired oxygen ($FiO_2$) at baseline was prognostic for opaganib treatment responsiveness and corresponded to disease severity markers. Patients with $FiO_2$ levels at or below the median value (≤60%) had better outcomes after opaganib treatment (n=117) compared to placebo (n=134). The proportion of patients with ≤60% $FiO_2$ at baseline that no longer required supplemental oxygen (≥24 hours) by day 14 of opaganib treatment increased (76.9% vs 63.4%: p-value =0.033). There was a 62.6% reduction in intubation/mechanical ventilation (6.84% vs 17.91%; p-value=0.012) and a clinically meaningful 62% reduction in mortality (5.98% vs 16.7%; p-value=0.019) by day 42. No new safety concerns observed. Conclusions: Post-hoc analysis supports opaganib benefit in COVID-19 severe pneumonia patients that require lower supplemental oxygen (≤60% $FiO_2$). Further studies are warranted.
Introduction
Despite the global rollout of vaccines, severe COVID-19 pneumonia remains a significant clinical challenge. Current standard-of-care treatments, such as Remdesivir and Dexamethasone, have limitations, and the emergence of new variants can reduce the efficacy of antibody-based therapies.
This study evaluates Opaganib, a first-in-class, oral, host-targeted therapy. Unlike treatments that target viral proteins, Opaganib inhibits the human enzyme sphingosine kinase 2 (SK2), which the virus hijacks for replication. By targeting a host process, Opaganib is theoretically "variant-agnostic," potentially maintaining efficacy across various viral mutations while providing both anti-viral and anti-inflammatory effects.
Methods
Researchers conducted a global, randomized, double-blind, placebo-controlled Phase 2/3 trial across 60 sites.
Participants and Regimen
The study included 475 hospitalized patients with severe COVID-19 pneumonia (WHO Ordinal Scale level 5). Participants were randomized to receive either 500mg of Opaganib or a matching placebo twice daily for 14 days, in addition to local standard of care (which included corticosteroids in 94% of cases).
Endpoints
The primary endpoint was the proportion of patients who no longer required supplemental oxygen for at least 24 hours by Day 14. Secondary endpoints included viral clearance rates, intubation rates, and mortality at 28 and 42 days.
Analysis Sets
The modified Intention-to-Treat (mITT) population consisted of 463 patients. Following initial broad analysis, the study focused on a sub-population of 251 patients who required $\le 60\%$ Fraction of Inspired Oxygen ($FiO_2$) at baseline.
Results and Key Insights
The Threshold of Irreversibility
While the drug did not meet its primary endpoint in the broad population, a critical insight emerged: "severe" is a heterogeneous category. Opaganib was highly effective in patients who were relatively less severely ill (those requiring $\le 60\% FiO_2$). This suggests a "threshold of irreversibility" in COVID-19 lung damage where host-targeted anti-inflammatories may lose efficacy if administered too late.
$FiO_2$ as a Precision Metric
The study demonstrated that $FiO_2$ (the actual concentration of oxygen delivered) is a more powerful prognostic marker for treatment response than the type of delivery device (e.g., nasal cannula vs. mask).
Clinical Outcomes in the $\le 60\% FiO_2$ Sub-group
In the pre-specified sub-population requiring $\le 60\% FiO_2$ at baseline, Opaganib showed significant benefits:
- Oxygen Independence: 76.9% of Opaganib patients achieved room air by Day 14, compared to 63.4% in the placebo group ($p=0.033$).
- Intubation/Ventilation: There was a 62.6% reduction in the rate of intubation or mechanical ventilation (6.84% for Opaganib vs. 17.91% for placebo; $p=0.012$).
- Mortality: The study found a 62% reduction in mortality by Day 42 (5.98% vs. 16.7%; $p=0.019$).
Viral Clearance and Safety
Opaganib significantly shortened the time to viral clearance (median 10 days vs. >14 days for placebo) across the broad population. The drug was generally well-tolerated, with slightly higher rates of mild gastrointestinal and neuropsychiatric events (such as insomnia) compared to placebo, while respiratory disorders were more frequent in the placebo arm.
Discussion and Limitations
The primary limitation of these findings is that the most significant results were derived from a post-hoc analysis. While the $FiO_2$ stratification was based on biological markers of severity, post-hoc results are considered hypothesis-generating and require prospective validation.
Additionally, a "site anomaly" at one location (Site 114) involved an unusually high mortality rate and an imbalance in randomization, which may have confounded the results for the broader population.
Conclusion
Opaganib shows significant promise for reducing mortality and the need for mechanical ventilation in patients with severe COVID-19 pneumonia who require lower levels of supplemental oxygen. Further prospective clinical trials are warranted to confirm these findings in the identified sub-population.
Summary updated